Antisoma/Novartis experimental drug hits the proverbial wall on Phase III lung cancer trial. Study halted.
New test may predict which MS patients will most benefit from beta interferons. This is actually a big deal – Researchers at Stanford University analyzed mice with an induced disorder similar to MS and blood samples saved from humans with the disease. They found two different subtypes of disease, each driven by excess activity of a different set of infection-fighting immune cells. Only the patients with one sub- type responded to the MS drugs known as beta interferons…more
Credibility, disclosure, Sanofi, Multaq, paid consultants. At the very least, not a real good “sniff test” here.
Speaking of disclosure, let me mention how we handle reporting pharma news, and making commentary at Impactiviti. Essentially, I call it like I see it – the good, the bad, and the ugly. Many of the companies mentioned in this blog are clients of Impactiviti. I am quick to highlight what is praiseworthy, and I don’t hesitate to call out deficiencies – whether a company happens to be a client or not. It is my hope to live, consult, and report with integrity, and my clients know to expect impartial writing and commentary here.
Negotiations Training – Impactiviti’s vendor/partners have just what you need to help your account managers (and others) become more skilled negotiators. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
The latest Impactiviti Connection e-newsletter is up! You can subscribe here.
Do pictures of insects covered with dew sound a bit gross. Trust me – these stunning photos are anything but!
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Leave a Reply